key: cord-0965429-y6ee0fh9
authors: Khurana, Ananta; Katare, Anusha; Agarwal, Aastha; Kathirvel, Priyadharshini; Ahuja, Arvind
title: Hydroxychloroquine induced erythroderma: a rare adverse effect of a commonly used drug
date: 2020-08-06
journal: Dermatol Ther
DOI: 10.1111/dth.14145
sha: d664c9281d469cc559ff0606469eeca9d4c4b758
doc_id: 965429
cord_uid: y6ee0fh9

nan

The authors declare no conflict of interest.

Hydroxychloroquine is considered a relatively safe drug when used for prolonged durations.

We report a patient of rheumatoid arthritis (RA) who developed erythroderma with its use over a short span of time and review relevant literature on this association.

A 23 years old female presented with generalised skin redness and scaling for a month. She had no history of any preceding cutaneous disease.The patient had been diagnosed with RA 4 months prior, and was started on hydroxychloroquine, sulfasalazine and NSAIDS (SOS) by a rheumatologist. However, she reportedly developed a generalized cutaneous rash with intense redness and scaling all over the skin surface a month later. The patient consulted a general physician, who diagnosed the condition as exfoliative dermatitis and stopped all her drugs. The physician also started oral steroids on which the rash resolved within 3 weeks.

However, considering sulfasalazine as the culprit, her rheumatologist later re-started hydroxychloroquine following which her rash re-occurred within one month. At presentation, the patient had generalised erythema and scaling diffusely involving the face, This article is protected by copyright. All rights reserved.

both upper limbs, trunk, both lower limbs and scalp (Figure 1 -a,c), with fissuring over both ankles, wrist, inguinal folds, palms and soles. She also had generalised lymphadenopathy and facial and pedal edema. Nails and all mucosae were normal.

Her laboratory parameters were hemoglobin-11.3 g/dl, white blood cell count-12,000 cells/cumm, erythrocyte sedimentation rate-29 mm/1st h and C-reactive protein >10mg/dL. RA factor was positive and absolute eosinophil count was 750/µL (normal range: 40-400cells/µL). Other biochemical parameters were normal. Viral markers were non-reactive.

Skin biopsy from the back showed parakeratosis, marked spongiosis and a eosinophil predominant dermal infiltrate consistent with drug induced erythroderma. (Figure 2 ,3) Naranjo adverse drug reaction (ADR) probability scale score was 9 (Table 1) This article is protected by copyright. All rights reserved. Hydroxychloroquine is commonly used in treatment of autoimmune and rheumatological conditions. The main mechanism for its anti-rheumatic effect is an interference with "antigen processing" by increasing vacuolar pH within antigen presenting cells. In the current times, hydroxychloroquine has also found worldwide use as a prophylactic and therapeutic agent against COVID-19. 1 The drug has a good tolerability with gastrointestinal adverse effects being an occasional reason for drug discontinuation.The incidence of antimalarial associated pruritus and cutaneous eruptions has been reported to be 10%-20%. 2 phenytoin, isoniazid, lithium and co-trimoxazole. 3 There has been only one previous report of hydroxychloroquine induced erythroderma, described in a patient of systemic lupus erythematosus (SLE) who developed erythroderma a month into treatment 3 , while hydroxychloroquine induced DRESS has been reported a few times before. 4 Another report mentions development of psoriatic erythroderma in a patient with coexistent psoriasis and SLE. 5 Although antimalarial induced exacerbation of psoriasis and induction of erythroderma in psoriatics is possibly related to inhibition of transglutaminase and resultant decreased epidermal differentiation 6 , the mechanism of induction of de novo erythroderma by the drug , as in our patient, remains to be elucidated in view of the rarity of the condition.

In a patient on multiple drugs like the presented one, the suspicion undoubtedly goes onto the drug with maximum reports in literature -like sulfasalazine here. However, in severe cases, often multiple drugs may be needed to be stopped as the culprit drug isn't obvious and, although uncommon, a true multiple drug hypersensitivity may also develop. 7 Further, a rechallenge is avoided in severe ADRs though it was inadvertently done in our patient, lending further weight to the association, as determined by Naranjo scoring.

With a wider use of hydroxychloroquine in the present times, beyond rheumatological conditions, and by medical specialists with less prior experience with the drug, it is pertinent to be aware of this rare but potentially severe drug complication. Finally, a severe CADR is also a known risk factor for development of further severe CADRs. 7 This risk needs to be This article is protected by copyright. All rights reserved.

understood by the treating clinician and explained to the patient, especially those with chronic diseases requiring prolong multi drug treatment. References:

This article is protected by copyright. All rights reserved.

A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID

Hydroxychloroquine in dermatology and beyond: Recent update

A review of the diagnosis and management of erythroderma (generalized red skin)

Pustular DRESS Syndrome Secondary to HydroxychloroquineWith EBV Reactivation

Hydroxychloroquine-Induced Psoriasis-formErythroderma in a Patient with Systemic Lupus Erythematosus

A Review of Drugs that Induce or Exacerbate Psoriasis